Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The clinical features of the condition are back pain and progressive stiffness of the spine. The main gene associated with susceptibility to ankylosing spondylitis is called HLA-B27. The mean global prevalence of AS per 10,000 has been found to be 23.8 in Europe, 16.7 in Asia, 31.9 in North America, 10.2 in Latin America and 7.4 in Africa.
Treatment options for ankylosing spondylitis include use of non-steroidal anti-inflammatory drugs, corticosteroids, disease modifying anti-rheumatic drugs and biologic agents all of which act on blocking the proteins involved in the body's inflammatory process. However, the overall response to the drugs remains unsatisfactory. In advanced/severe cases, surgical management may be indicated.
Progenitor cells in the human body have been shown to have immune-regulatory, anti-inflammatory and tissue repairing properties. Cellular therapy is a feasible, safe, and promising treatment modality for patients with AS.
Our protocol involves harvesting cells from the patients' own body (autologous stem cells). After activation the cells are transplanted into the appropriate site. The degree of improvement achieved will depend on the stage of the condition, presence of other influencing factors and patient compliance with respect to following diet and allied therapies (physiotherapy, yoga).